Header

UZH-Logo

Maintenance Infos

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial


Prince, H Miles; Kim, Youn H; Horwitz, Steven M; et al; Dummer, Reinhard (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094):555-566.

Statistics

Altmetrics

Downloads

0 downloads since deposited on 07 Jun 2017
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:June 2017
Deposited On:07 Jun 2017 12:07
Last Modified:04 Aug 2017 01:02
Publisher:Elsevier
ISSN:0140-6736
Publisher DOI:https://doi.org/10.1016/S0140-6736(17)31266-7

Download

Preview Icon on Download
Content: Published Version
Filetype: PDF - Registered users only
Size: 642kB
View at publisher

Author Collaborations